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Although replication-incompetent herpes simplex virus (HSV) vectors have the capability to express foreign genes, suc-
cessful development of these vectors for gene delivery would require that expression of the foreign gene be regulated. To
investigate the feasibility of obtaining inducible expression of a foreign gene in such a vector, a replication-incompetent
HSV vector, vd120/LTRb, was developed that used the human immunodeficiency virus type 1 (HIV-1) long terminal repeat
(LTR) to express the Escherichia coli lacZ gene. Examination of lacZ expression from the HIV-1 LTR in vd120/LTRb-infected
cells indicated that the LTR was active as a promoter under both replicating and nonreplicating conditions, although
expression of lacZ under nonreplicating conditions was approximately 4-fold lower. In addition, the LTR expressed lacZ in
a manner distinct from that of well-characterized HSV-1 promoters of each temporal class. The effect of the HIV-1 regulatory
protein Tat on expression from the LTR in vd120/LTRb was examined by infection of two different HeLa-derived cell lines
that constitutively expressed Tat, HL2/3, and HLtat. Compared to infection of HeLa cells, lacZ expression from vd120/LTRb-
infected HL2/3 and HLtat cells increased from 4- to 24-fold, depending on the multiplicity of vector infection. Sustained
expression of lacZ from the LTR in vd120/LTRb-infected cells was not observed even in the continuous presence of Tat,
although vector could be recovered for up to 5 days after infection. However, the amount of recoverable vector decreased
during this time, suggesting that cellular cytotoxicity may account for some of the decrease in Tat-mediated expression
from the LTR. q 1996 Academic Press, Inc.
Recombinant herpes simplex viruses that express for- of reduced expression of the viral immediate-early genes
eign genes have potential for use as gene delivery and (3, 4), and the development of several methods to facili-
gene therapy vectors. Herpes simplex virus type 1 (HSV- tate recombinant virus construction (5–7). Another obsta-
1), in particular, has several characteristics that make it cle that is common to the development of any gene ther-
attractive for development as a gene delivery vector. apy vector is the attainment of regulated and long-term
These include the ability to express high levels of foreign expression of the desired foreign gene. To date, the most
genes, the capability to infect a wide variety of cell types, common approach in regulating foreign gene expression
and the ability to establish a nonlytic life-long latent infec- has been through the use of different promoters, in the
tion in sensory neurons. In addition, with the use of repli- expectation that some might have the ability to be ex-
cation-incompetent HSV vectors, gene delivery to non- pressed either to high levels or for extended periods
neuronal cells is feasible, where lysis rather than latency after vector delivery (8–15).
is the usual outcome of infection (1, 2). In previous work, we demonstrated that a replication-
However, significant obstacles still remain in the de- incompetent HSV vector that expressed interferon-a
velopment of recombinant herpes simplex viruses as (IFN-a) inhibited human immunodeficiency virus (HIV)
vectors for gene delivery. Some of these obstacles are replication in human monocytes (15). A vector-delivered
unique to HSV, such as the cytotoxicity associated with antiviral gene such as IFN-a would be more effective
vector infection even in the absence of vector replication, and safer if it were expressed at high levels only in HIV-
and the difficulties associated with manipulation of the infected cells (16). The aim of the present work was to
viral genome. Efforts to overcome these problems have determine whether we could obtain such conditional
resulted in a reduction of vector cytotoxicity as a result gene expression in an HSV vector. To test a model of
inducible gene expression, we examined the ability of
the HIV-1 long terminal repeat (LTR) to direct foreign
1 To whom correspondence and reprint requests should be ad- gene expression in a replication-incompetent HSV vec-dressed at Division of Viral Products, HFM-457, Center for Biologics
tor. Our choice of the HIV-1 LTR was based primarily onEvaluation and Research, 1401 Rockville Pike, Rockville, MD 20852.
Fax: (301) 480-6124. e-mail: weirj@a1.cber.fda.gov. the fact that during HIV-1 infection, the HIV-1 promoter,
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FIG. 1. Structure of the replication-incompetent HSV vector vd120/LTRb. (A) Schematic diagram of the genomic structure of recombinant vector
vd120/LTRb. Promoter sequences from the HIV-1 LTR (bp 1-533) (32) were cloned by PCR and inserted into the vector pGal8 (33), and the resulting
plasmid pLTR-Gal was recombined into HSV-1 d120 at the thymidine kinase (TK) gene. (B) Southern blot of recombinant vector vd120/LTRb. DNA
was isolated from E5 cells infected with either of two isolates of vd120/LTRb (lanes 1 and 2) or d120 (lane 3), digested with EcoRI, and probed
with either a 32P-labeled tk fragment or a 32P-labeled lacZ fragment (450 bp). The 2.4-kb fragment that contains the tk gene increased in size to
approximately 6 kb after insertion of the LTR/lacZ gene.
located in the viral LTR, is strongly inducible by the HIV reported, expression from the immediate-early ICP0 pro-
moter is much higher in the absence of ICP4 and virusTat regulatory protein (17).
The HIV LTR was inserted upstream of an Escherichia replication (7) (Fig. 2D; note scale difference). These re-
sults indicated that the LTR was active as a promoter incoli lacZ marker gene and recombined into the replica-
tion-incompetent herpes simplex virus d120 (Fig. 1A). The a recombinant HSV vector, both in the presence and in
the absence of virus replication. Thus, the LTR expressesvirus d120 has a large deletion in the essential ICP4
gene and replicates only in cell lines such as E5 that lacZ in a replication-incompetent vector in a manner dis-
tinct from that of well-characterized HSV-1 promoters ofcan complement this defect (18). Upon infection of other
cells, only the four remaining immediate-early genes and each temporal class. This may be due to the fact that
the LTR contains multiple transcriptional regulatory ele-the gene encoding ICP6 are expressed at appreciable
levels (19). Two individual recombinant virus isolates ments, some or all of which may be responsible for ex-
pression in vd120/LTRb-infected cells in the absencewere analyzed by DNA blotting to verify the expected
structure (Fig. 1B). of Tat.
The ability of the HIV LTR in vd120/LTRb to be trans-The ability of the HIV LTR to direct expression of the
lacZ gene was examined initially by infection of E5 and activated by the HIV regulatory protein Tat was examined
by infection of cells that constitutively expressed Tat.Vero cells with vd120/LTRb (Fig. 2). Under replicating
conditions (infection of E5 cells), b-Gal activity was de- HLtat and HL2/3 cells are stable transfectants of HeLa
cells that have been selected for their ability to producetected at 4 hr postinfection and continued to rise for at
least 24 hr. Under nonreplicating conditions (infection of Tat. HLtat cells contain the HIV LTR linked to a synthetic
one-exon tat gene (20); HL2/3 cells contain integratedVero cells), b-Gal activity was detected at each timepoint,
although at lower levels than observed in E5-infected copies of the HIV-1 clone HXB2/3gpt and express the
HIV Gag, Env, Rev, and Nef gene products, in additioncells. For comparison, Vero and E5 cells were infected
with three other replication-incompetent vectors that to Tat (21). HeLa, HLtat, and HL2/3 cells were infected
with vd120/LTRb and examined for the expression ofused different temporal classes of HSV-1 promoters to
express lacZ (Fig. 3B-D). Although both the late gC pro- lacZ at 24 hr (Fig. 3). Expression of the lacZ gene in
vd120/LTRb-infected HLtat and HL2/3 cells was in-moter (Fig. 2B) and the early tk promoter (Fig. 2C) ex-
pressed lacZ during virus replication, expression from creased 8.5- and 4-fold, respectively, relative to the ex-
pression of lacZ in HeLa cells. In contrast, expression ofboth promoters was dramatically reduced in Vero cells
in the absence of ICP4 and virus replication. In fact, no lacZ gene in vd120/b-Gal infected HLtat and HL2/3 cells
was only 2-fold higher than in vd120/b-Gal-infected HeLab-galactosidase activity was detected from the late gC
promoter; only a very low activity was detected from the cells. No lacZ expression was detected in d120-infected
cells. Similar vector infections were performed in 8E5tk promoter at 18 and 24 hr postinfection. As previously
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FIG. 2. Infection of Vero and E5 cells with replication-incompetent HSV vectors expressing lacZ. Vero (n) or E5 (h) cells were infected with
replication-incompetent HSV vectors and at the indicated times were collected by scraping and centrifugation and assayed for b-galactosidase
activity. (A) Infection with vd120/LTRb. (B) Infection with vd120/gCL5 (glycoprotein C promoter). (C) Infection with vd120/tk (thymidine kinase promoter).
(D) Infection with vd120/b-Gal (ICP0 promoter). All replication-incompetent vectors designated by the prefix d120 were derived from the replication-
incompetent virus d120 (18), and they were grown and titered in the ICP4-complementing cell line E5 (19). Vectors vd120/gCL5 and vd120/tk were
generated by recombination into d120 using the plasmids pgCL5 (34) and pTK-Gal (35). The HSV vector vd120/b-Gal has been described previously
(15, 7). Cells were infected at a multiplicity of infection (m.o.i.) of 5 and the synthesis of b-galactosidase was measured at the indicated times after
infection, essentially as described by Miller (36) but adapted for 96-well plates.
cells, an HIV-1-infected A3.01 T cell line that produces the absence of replication. Consequently, we infected
cells with vector at a multiplicity of 0.1 to minimize cyto-reverse transcriptase defective HIV particles (22). Ex-
pression of the lacZ gene in vd120/LTRb-infected 8E5 toxicity and measured the b-Gal activity in infected HeLa
and HLtat cells at 1, 3, and 5 days postinfection (Fig. 4).cells was increased 6.5-fold relative to the expression in
A3.01 cells (data not shown). Furthermore, primer exten- At the low m.o.i. of infection, the relative effect of Tat on
lacZ expression from the LTR in vd120/LTRb was evension analysis of RNA isolated at 24 hr after vd120/LTRb
infection of HLtat cells revealed that the lacZ mRNA was more dramatic. Expression of lacZ at 24 hr postinfection
was over 26-fold greater in HLtat cells than in HeLa cells.initiated at the normal site of transcription in the LTR
(data not shown). These results indicate that the LTR, However, b-Gal activity peaked at 1 day after infection
of each cell type with vd120/LTRb and continued to de-incorporated into the genome of an HSV vector, was
transactivated by Tat. cline for 5 days. This same relative pattern of lacZ expres-
sion was seen in vd120/b-Gal-infected HLtat and HeLaWe wished to examine whether lacZ would continue
to be expressed for an extended time in vd120/LTRb- cells. To determine whether the vector remained in the
cells during this 5-day period, we attempted to recoverinfected cells in the presence of Tat. Experimentally, such
an analysis presented problems since the vector does vector DNA with a superinfection rescue technique (23,
24), using the replication-incompetent virus 5dl1.2. Thisnot replicate, but the cells continue to divide. Further-
more, d120-derived vectors are cytotoxic to cells even in virus has a deletion in the essential immediate-early
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that either HSV early or late promoters can be used to
direct foreign gene expression, since both types of pro-
moters require ICP4 for expression (for example, Fig. 2).
Several nonherpesvirus promoters, such as the rabbit b-
globin and the human a2-globin genes, have been in-
serted into both replication-competent and ICP4 replica-
tion-incompetent herpes viruses, but these promoters
also require ICP4 for expression and function (27). In
contrast, other non-HSV promoters, such as the SV40
early promoter (28), the Moloney murine leukemia virus
LTR (10, 29), and the neuron-specific enolase gene pro-
moter (12), have been shown to be active in ICP4 virus
vectors, suggesting that some non-HSV promoters might
be useful for directing foreign gene expression to neu-
rons as well as to other cell types.
The results presented here indicate that conditional
foreign gene expression might also be feasible in replica-
tion-incompetent HSV vectors. Expression from the LTRFIG. 3. Infection of HeLa, HLtat, and HL2/3 with vd120/LTRb. HeLa,
HLtat, and HL2/3 cells were infected with vd120/LTRb, vd120/b-Gal, was increased several-fold in vd120/LTRb-infected HeLa
or d120 at an m.o.i. of 5. At 24 hr, cells were collected by scraping and cell lines that constitutively expressed Tat. A similar in-
centrifugation and assayed for b-galactosidase activity. duction of lacZ in vd120/LTRb, relative to that of the con-
trol vector vd120/b-Gal, was observed in a T cell line
that expressed defective HIV particles. However, HIV-gene that encodes ICP27 and can only be propagated
in cell lines such as 3-3, which can complement this infected T cells would probably not be a suitable target
for HSV vector mediated gene delivery of antiviral genes.defect (25). Although this procedure does not easily dis-
tinguish between recovered virus that results from re- Unlike monocytes, T cells are dividing cells and are not
as easily infected with HSV vectors (J. P. Weir, unpub-combination versus virus that results from complementa-
tion, it provides a measure of the amount of vector DNA lished observations). Interestingly, expression from the
HSV-1 immediate-early promoter in vd120/b-Gal waspresent in cells at different days after infection. In addi-
tion, this technique permits detection of very low levels also increased in Tat-expressing HeLa cells, although
not to the extent of the increase observed using the LTR.of viral DNA (less than 1 copy per cell) without the diffi-
culties associated with quantitative PCR. HLtat cells, on It is not clear whether this is due to increased infectivity
Days 1, 3, and 5 after vd120/LTRb infection, were super- of these cells, relative to HeLa cells, a direct effect of
infected at an m.o.i. of 10 with 5dl1.2, and the virus recov- Tat on the immediate-early promoter, or some other con-
ered 1 day later was titered on E5 cells. No virus was sequence of cell selection that occurred during cloning
recovered in cells that were mock-infected with 5dl1.2. of the cell line. Infection of all three HeLa cell lines with
The log of the virus titer recovered on Day 1 after vd120/
LTRb infection was 4.38 { 0.04 ({SE); on Day 3 the titer
was 3.29 { 0.08; on Day 5 the titer was 2.65 { 0.65.
Thus, the amount of virus recovered from HLtat cells
decreased by almost 10-fold from Day 1 to Day 3 and
decreased another 2-fold by Day 5. These results sug-
gest that the cytotoxicity of d120-derived vectors in HLtat
cells may account for some of the decrease in expression
from the LTR even in the continuous presence of Tat. It
is also possible that the vector infection of these cells
alters Tat expression and thus affects expression from
the LTR.
Several different promoters have been used to direct
foreign gene expression in herpes simplex virus vectors.
Some, such as the immediate-early promoter from the
gene encoding ICP0 and the human CMV IE promoter,
direct high levels of foreign gene expression in ICP40
FIG. 4. Time course of lacZ expression in vd120/LTRb-infected cells.
vector-infected cells, but the expression appears to be HeLa and HLtat cells were infected with vd120/LTRb at a multiplicity
short-lived (7, 13–15, 26) (Figure 2). The lack of ICP4 in of 0.1. At the indicated day after infection, cells were collected and
assayed for b-galactosidase activity.a replication-incompetent HSV vector makes it unlikely
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